In fact, our work confirms and extends this data by showing a clear potential of heparanase activity and heparan sulfate plasma levels as promising biomarkers for the prediction of disease severity and outcome of COVID-19 patients admitted to the ICU. This evidence concerns the gene HPSE and COVID-19.